Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation

Denosumab is an anti-RANKL Ab that potently suppresses bone resorption, increases bone mass, and reduces fracture risk. Discontinuation of denosumab causes rapid rebound bone resorption and bone loss, but the molecular mechanisms are unclear. We generated humanized RANKL mice and treated them with d...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Qiang, Bustamante-Gomez, Nancy C., Reyes-Pardo, Humberto, Gubrij, Igor, Escalona-Vargas, Diana, Thostenson, Jeff D., Palmieri, Michela, Goellner, Joseph J., Nookaew, Intawat, Barnes, C. Lowry, Stambough, Jeffrey B., Ambrogini, Elena, O’Brien, Charles A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561722/
https://www.ncbi.nlm.nih.gov/pubmed/37581932
http://dx.doi.org/10.1172/jci.insight.167790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561722/
https://www.ncbi.nlm.nih.gov/pubmed/37581932
http://dx.doi.org/10.1172/jci.insight.167790

Ejemplares similares